• Bicycle Therapeutics outlined an oncology-focused pipeline built on its Bicycle molecules platform, spanning drug conjugates, radioligands, and imaging agents.
• Lead asset nuzefatide pevedotin targets EphA2, positioned as first-in-class; Phase 2 open-label trial underway in second-line or later pancreatic cancer.
• Presentation highlighted tolerability at clinically active doses; 161 patients exposed in BT5528-100, with no hemorrhage events reported to date.
• Company reported cash and cash equivalents of USD 510.1 million as of June 30, 2026, with expected runway into 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.